相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond
Mark P. Lythgoe et al.
EUROPEAN JOURNAL OF CANCER (2021)
Evaluation of Aducanumab for Alzheimer Disease Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility
G. Caleb Alexander et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Dangling Accelerated Approvals in Oncology
Julia A. Beaver et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval
Kerrington Powell et al.
JAMA ONCOLOGY (2021)
Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada
Joanna Gotfrit et al.
ONCOLOGIST (2020)
FDA’s Oncology Center for Excellence Pilots Project Orbis: A framework for concurrent submission and review of oncology products among international partners.
Dianne Spillman et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Conditional approval of cancer drugs in Canada: accountability and impact on public funding
S. K. Andersen et al.
CURRENT ONCOLOGY (2019)
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics A Review
Julia A. Beaver et al.
JAMA ONCOLOGY (2018)
International variability in the reimbursement of cancer drugs by publically funded drug programs
P. K. Cheema et al.
CURRENT ONCOLOGY (2012)
分享论文
